Asp Isotopes Inc. · NASDAQ:ASPI
Asp Isotopes — Investor Presentation (October 2023)
36 slides from Asp Isotopes's investor presentation, Oct 3, 2023
Slide 1: Corporate Overview
ASP isotopes Corporate Overview October 2023
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements ‘This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private ‘Securities Litigation Reform Act of 1995. Forward-loo
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance BB 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the
Slide 4: Company History
Company History October 2021 . July 2022 March 2023 June 2023 ———— ange Ss Ss eee. ‘commenced procurement of components Kiydon ‘Small-Scale Plant highly Enriched Isotopes : : ; 2021 2022 2023 Scenes 2021 Jan/Feb 2022 November 2022 May 2023 ASP Incorporated in Delaware ‘Start discussions with the Ini
Slide 5: Isotope Production is Essential for National and Global Security
Isotope Production is Essential for National and Global Security Isotopes have one of the most severely compromised supply chains of Historical Isotope any material in the world and are Critical to the following end markets. Market Producers* Europe 15% — ‘The World remains susceptible to Global dis
Slide 6: What Is An Isotope?
What Is An Isotope? Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. * — Isotopes are two or more atoms of the same chemical element with the same number of protons and electrons but slightly different numbers of neutrons. + Isotopes a
Slide 7: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights 1. Cost-Effective = Ee] Isotope enrichment facilities using ASP technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. This technology has been refined for over 20 years through the South African Nuclear
Slide 8: ASP Technology: Stationary Wall Centrifuge
ASP Technology: Stationary Wall Centrifuge Benefits of a Stationary Wall Centrifuge No moving parts vs. a conventional centrifuge 1 2. No unique materials are required 3. Cost-efficient at small scale 4 High Separation Efficiency Zz ; | | Small Production = Flexible Capacity SS — a Modules Deploymen
Slide 9: Anticipated Milestones
Anticipated Milestones MARKET MILESTONES 1. Secure at least 2 additional supply agreements for isotopes critical for new technologies and healtheare. 2. Generate sufficient revenues for the company to have annual positive operating cash flow. 3. Enter additional supply contracts for new isotopes in
Slide 10: Isotopes of Interest
Isotopes of Interest Germanium-70/72/74 Molybdenum-100 Molybdenum-s8 Zine 67/68 Yiterbium-176 Nickel-64 Xenon-129/136 Chlorine-37 Lithium-6 Uranium-235 Under Commercially Isotopes End-Market R&D Stage R&D Evaluation Construction Available Carbon-14 Pharma & Agrochem [eee Silicon-28 Quantum Computing
Slide 11: Isotope End Markets: Nuclear Medicine
Isotope End Markets: Nuclear Medicine ISOTOPES OF INTEREST END MARKET Carbon-Dating PET Scan imaging Oncology Oncology SPECT Scan Treatment Treatment Pharmacokinetic Imaging Oncology (Non-Hodgkin (Neuroendocrine Tracing Treatment iymehome, Frostate ‘Tumors NETs) Cancer, NETS) ASP lotopes ine ASP iso
Slide 12: Isotope End Markets: Carbon-14 (14C)
Isotope End Markets: Carbon-14 (14C) Radiolabeling scientific technique used to track the passage of a molecule. The technique incorporates a radioisotope through a reaction, cell, organism, biological system, or metabolic pathway. Carbon-14 Used as a radiolabeling compound due to its’ relatively ha
Slide 13: Isotope End Markets: Molybdenum-100 and Zinc-68
Isotope End Markets: Molybdenum-100 and Zinc-68 Imaging Agent Distribution Single-photon emission 2 computed tomography (SPECT) Technetium-39 ore ie see of all SG Size® Technetium-998 $4 Meneses °8T¢ Global Market Size’ Imaging Agent Distribution Positron emission tomography CoC > er prost ancers CE
Slide 14: Nuclear Medicine Supply Chain
Nuclear Medicine Supply Chain Current Isotope Conversion Process Reactor Target Irradiation Current Mo99 Supply Chain Purified Mo-99/Te-99m Mo-99 Generators 7 Generator Manufacturer Hospitals, Pharmacies ASP Isotope Conversion Process 99Mlo => 9To Half-Life: 66 Hours Half-Life: 6 Hours 100110 o> [Te
Slide 15: Geopolitical Tailwinds for ASPI Nuclear Medicine
Geopolitical Tailwinds for ASPI Nuclear Medicine World's Largest Nuclear Facilities Manufacturing Isotopes 1. Government Support for Alternative Supply “Between 95 and 98 percent of Mo is currently being produced using highly enriched uranium (HEU) targets, which was the major concern of Congress."*
Slide 16: Silicon-28: Enabling Quantum Computing
Silicon-28: Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today's conventional computers and are widely anticipated to create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics, and other industries. The semiconductor
Slide 17: Market Opportunities of Other Isotopes
Market Opportunities of Other Isotopes For Use in Quantum Computing 1. Quantum computing requires ultra-pure Silicon-28 Which is not available at any price at commercial scale 2. ASP Intends to conduct further testing to enhance the current capability of enrichment of Si28 up to. commercial requirem
Slide 18: Future Growth Plans to Scale ASPI Business into new Isotopes
Future Growth Plans to Scale ASPI Business into new Isotopes Iceland identified as the likely optimal location for expansion: Iceland Electricity Network + Iceland's policy is to attract high-tech green industry into the country to support its own long-held ESG-based ethos. + Likely government suppo
Slide 19: Quantum Leap Energy
—s IANTUM LEAP ENERGY ASP isotopes ©
Slide 20: The Equation is a Well-Known Fact... Solving it is not Straightforward
The Equation is a Well-Known Fact... Solving it is not Straightforward Protesting is not going to Solve I ... The Solution Requires the Equation... At the same time, the world Innovation and Investment needs to acl neutrality. | & ASP isotopes
Slide 21: The Global Necessity for Increased Green Nuclear Energy
The Global Necessity for Increased Green Nuclear Energy 3 Poo) Increasing Demand for Energy _ S + Toreach Net Zero emissions by 2050, the world must increase Global Electricity generation by 250% and double Nuclear energy output." = Climate scientists recommend increasing the share of low-carbon ene
Slide 22: Nuclear Power Uptake Benefits
Nuclear Power Uptake Benefits Low Carbon Energy ] Nuclear power is one of the world's energy sources that emits the least greenhouse gas 70x less CO2 than gas 40x less CO2 than coal 4x less CO2 than solar ASP iat Constant and Controllable Energy Essential Energy Diversity Nuclear power provides cont
Slide 23: SMR (Small Modular Reactors) = Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower's Natrium = Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater a flexibility in deployment = = Designed for production-line manufacturing rather than conve
Slide 24: HALEU Supply Issue
HALEU Supply Issue Looming for SMR Reality = Current commercial LWRs use low-enriched uranium (LEU) which has less than 5% ”°5U content. + Many SMRs and advanced reactors will require High ‘Assay Low Enriched Uranium (HALEU) with 2%U enrichment up to 19.75%. * Currently, there is no commercial sourc
Slide 25: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods Gaseous Diffusion Molecular Laser Isotope ‘Separation (MLIS) Atomic Vapor Laser Isotope Separation (avis) Silex Systems Quantum Enrichment {used by QLE) Capital 1/10 of = Selectivity a 2 Selectivity swu — 500 Stages to Required reactor grade High capital
Slide 26: What is Quantum Enrichment?
What is Quantum Enrichment? Quantum Enrichment was derived from AVLIS (Atomic Vapor Laser Isotope Separation). Isotopes of every element also have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. Quantum enrichme
Slide 27: Nuclear Fuel Cycle
Nuclear Fuel Cycle Estimated World Primary Conversion Capacity 2020 Estimated World Primary Enrichment Capacity 2020 : ‘Nameplate Capacity Capacity 2020 Capacity (Thousand eeu! ae oe Capacity (1) Utilization (6) _ Utilization (QU) country ‘Company and Pant swu/y) France ‘Areva, Georges Base Bt 7500
Slide 28: Nuclear Fuel Prices are at 10-Year Highs
Nuclear Fuel Prices are at 10-Year Highs Multiple Macroeconomic factors caused by geopolitics, pandemics, blocked canals, and weather, have caused long-term Uranium price indicators to continue to rise to 10-year highs. Front-end nuclear fuel markets highlight numerous and increasing risks facing th
Slide 29: Current Implications of Depleted UF6 tails
Current Implications of Depleted UF6 tails Depleted tails from other Uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. Our Process has the ability to process this waste into HALEU Potentially providing a solution to this growing environmental problem Deplet
Slide 30: Production Profile — Next 10+ years
Production Profile — Next 10+ years The company initially expects to process low-enriched uranium (LEU) as a feedstock. This allows us to rapidly increase the production volumes to meet the near-term demand of our customers. A laser system produces substantially more HALEU when using LEU as a feedst
Slide 31: Investment Thesis
Investment Thes ER 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the growing d
Slide 32: Management Team
Management Team (©AS? totes le ASP isotopes»
Slide 33: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN Chairman, and CEO Co-founded ASP Isotopes in September 2021 20+ years of experience on Wall Street investing in healthcare and chemicals companies at Soros Fund Management, Highbridge Capital and Morgan Stanley. MA and MEng (Chemical Engineering) from Cambridg
Slide 34: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors EINAR RONANDER BS Chief Scientific Advisor + Globally recognized as a leading scientist in the field of isotope separation for medical and industrial applications + Pioneered the Molecular Laser Isotope Separation (MLIS) and the Atomic Vapour Laser Isotope Separatio
Slide 35: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors DUNCAN MOORE, PhD Eig Director Partner at East West Capital Partners, specializing in investment opportunities within the Healthcare Industry across the APAC region. Global Head of Healthcare Equity Research at Morgan Stanley from 1991 to 2008, MPhil & PhD in Bi
Slide 36: Data Sources
Data Sources Wang, Yi to Producton Review ot Acer Sane Medal lcops Mcecdes (asa Swzran) wh 27,16 S294 19 Au, 202, do 10.36Oheec den 15204, BL 2aov et a “Prometen of medcalradonudiesn Fuss: Sue and hee a eo” App Raat of nd utopes, ene, February 2014, Mp tek ef. 106) apn 2013.11.05. ero NP, Meck, Tame